联系方式

办公电话:020-39943026

电子邮箱:liupq@mail.sysu.edu.cn

办公地址:

简单介绍

刘培庆,19644月出生,医学博士,教授,博士生导师,享受国务院政府特殊津贴专家,中山大学药理学国家重点学科带头人之一,中山大学卓越人才计划高层次人才,2016入选广东省特支计划杰出人才(南粤百杰),2017年广东省珠江人才计划首批本土创新科研团队负责人。现担任新药成药性评估及评价国家地方联合工程实验室(国家发展改革委授牌)主任,国家新药成药性研究工程技术研究中心(培育)主任,国家重点培育平台新药成药性研究国家工程实验室召集人,科技部重大新药创制药效学(心血管)平台组长,广东省新药成药性评估及评价工程实验室主任,广州市生物活性化合物成药性评价重点实验室主任,2012年度科学中国人年度人物。担任中山大学药学院药理与毒理学实验室主任,新药研究开发中心主任。目前正在负责21类新药的临床前研究。现任全国转化医学产业学会副会长、中国整合药学联盟副理事长,中国药理学会理事、广东省药理学会理事长、广东省人事厅博士后协会(联谊会)理事长、中国药理学会表观遗传药理学专业委员会副主委,以及心血管药理等3个专业委员会常委等。主要从事心血管药理学及分子生物学研究,研究方向为高血压心肌肥大的信号转导机制、比较蛋白质组学、动脉粥样硬化的发病机制及相关新药研究。担任国家科学技术奖评奖专家、国家重大专项审评专家、国家自然科学基金二审专家及教育部专项审评专家,广东省重大行政决策咨询论证专家、广东省市科技项目、科学技术奖及新药审评论证专家等,广东省知识产权局第二届广东专利奖评审委员会医药评审组组长。担任《中华现代内科学杂志》常务编委、《药学研究》、《药学实践》等杂志编委等。兼任华南理工大学讲座教授、广州中医药大学客座教授等。获得广东省科学技术一等奖、教育部科技成果二等奖(主要成员),广东省科学技术一等奖(第一完成人),以专利发明人或主要成员申请国家发明专利33项,其中16项已获授权。Circulation ResBr J PharmacolOncogeneExp Cell ResInflammation等杂志审稿人。指导博士研究生40多名,硕士研究生90多名,已毕业者全部获得硕士学位,毕业的博生基本都获得了国家自然科学基金资助,还获得了广东特支计划青年优秀人才、羊城学者、珠江新星等荣誉。

科研项目

先后主持国家自然科学基金9项、科技部重大新药创制科技重大专项3项、广东省自然科学基金团队项目等3项,教育部及广东省市重点重大项目9项,累计经费超过5千万元。近五年作为负责人承担或完成的项目,具体如下:

1. 国家自然科学基金面上项目,81872860,组蛋白去甲基化酶JMJD3调控病理性心肌肥大的表观修饰机制研究,2019/01-2022/1260万元,在研,主持。

2. 广东省本土创新科研团队,2017BT01Y093,炎症相关性重大疾病创新药物研发及关键技术,2018-20231000万元,带头人。

3. 广东省产学研合作领域,2017B090903004,国家新药成药性评价工程技术研究中心培育,2018/01-2020/12300万元,中心负责人。

4. 国家重大新药创制科技重大专项,2018ZX09301031-001PDE9A抑制剂LW33作为治疗阿尔茨海默病1.1类化学药的临床前研究,2018/01-2020/12294.16万元,在研,主持。

5. 国家自然科学基金面上项目,81673433FoxO3PAR化修饰及其调控病理性心肌肥大的机制,2017/01-2020/1260万元,在研,主持。

6. 南粤百杰(广东省特支计划杰出人才),2016年,药理学,100万。

7. 广州市科技计划项目产学研协同创新重大专项,201604020121,选择性PDE9A抑制剂LW33治疗老年痴呆的临床前研究,2016/04-2019/03200万元,在研,主持。

8. 广东省应用型科技研发专项资金项目,2015B020232009PDE9A抑制剂LW33作为治疗阿尔兹海默病1.1类化学药的临床前研究,2016/01-2018/12500万元,在研,主持。

9. 国家自然科学基金面上项目,81473205,从SIRT3调控角度研究病理性心肌肥大的能量代谢异常机制,2015/01-2018/1280万元,在研,主持。

10. 广东省科技厅公益研究与能力建设专项,2014B020210003,新药筛选及成药性评价关键技术研究,2015/01-2018/12100万,在研,主持。

11. 中山大学卓越人才计划高层次人才,2014年,药理学。

12. 广东省创新载体建设项目,2013B090700010,新药成药性评估及药效学评价集成创新产学研平台,2014/12-2017/1280万元,申请结题,主持。

13. 国家自然科学基金面上项目,81273499,转录辅助抑制因子RIP140在心力衰竭中的转录调控机制研究,2013/01-2016/1280万元,已结题,主持。

14. 广东省科技计划重大项目,2012A080201007,多靶点抑制剂W7作为防治老年性痴呆1类新药的临床前研究,2013/01-2015/12100万,已结题,主持。

论著专利

近年来通讯发表SCI论文超过100篇(累积影响因子超过500,他引超过5000次)。以专利发明人或主要成员申请国家发明专利33项,其中16项已获授权。主编及参编专著8部。

 5年以通讯作者发表的SCI论文:

  1. Fu Y#, Hong L#, Xu J#, Zhong G#, Gu Q, Gu Q, Guan Y, Zheng X, Dai Q, Luo X, Liu C, Huang Z, Yin XM, Liu P* and Li M*. Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo. Autophagy. 2018:1-17.
  2. Li J#, Huang J#, Lu J#, Guo Z, Li Z, Gao H, Wang P, Luo W, Cai S, Hu Y, Guo K, Wang L, Li Z, Wang M, Zhang X* and Liu PQ*. SIRT1 represses PKC-zeta activity via regulating interplay of acetylation and phosphorylation in cardiac hypertrophy. Br J Pharmacol. 2018.
  3. Hu Y#, Guo Z#, Lu J*, Wang P, Sun S, Zhang Y, Li J, Zheng Q, Guo K, Wang J, Jiang J* and Liu PQ*. sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and Rats. Arch Toxicol. 2018.
  4. Lu J#, Li JY#, Hu YH, Guo Zhen, Duan DY, Sun DP, Wang PX, Guo KT, Gao S, Jiang JM, Wang Junjian* and Liu PQ*, Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation, Acta Pharmaceutica Sinica B, 2018.
  5. Sun DP#, Lu J#, Luo ZF, Zhang LY, Liu PQ* and Chen ZG*. Competitive electrochemical platform for ultrasensitive cytosensing of liver cancer cells by using nanotetrahedra structure with rolling circle amplification. Biosens Bioelectron. 2018;120:8-14.
  6. Guo Z, Lu J, Li JY, Wang PX, Li ZZ, Zhong Y, Guo KT, Wang JJ, Ye JT* and Liu PQ*. JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing beta-MHC expression. Mol Cell Endocrinol. 2018;477:1-14.
  7. Wang LP, Li ZM, Tan YZ, Li Q, Yang HW, Wang PX, Lu J* and Liu PQ*. PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy. Mol Cell Endocrinol. 2018;474:137-150.
  8. Wen WJ#, Chen JW#, Ding LG#, Luo X, Zheng XP, Dai Q, Gu QQ, Liu C, Liang M, Guo XL, Liu PQ* and Li M.* Astragaloside exerts anti-photoaging effects in UVB-induced premature senescence of rat dermal fibroblasts through enhanced autophagy. Arch Biochem Biophys. 2018;657:31-40.
  9. Luo WW#, Wang Y#, Yang HW, Dai CM, Hong HL, Li JY, Liu ZP, Guo Z, Chen XY, He P, Li ZQ, Li F, Jiang JM, Liu PQ* and Li ZM*. Heme oxygenase-1 ameliorates oxidative stress-induced endothelial senescence via regulating endothelial nitric oxide synthase activation and coupling. Aging-Us. 2018;10:1722-1744.
  10. Li ZM#, Xu SW# and Liu PQ*. Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta pharmacologica Sinica. 2018;39:802-824.
  11. Li ST, Dai Q, Zhang SX, Liu YJ, Yu QQ, Tan F, Lu SH, Wang Q, Chen JW, Huang HQ, Liu PQ* and Li M*. Ulinastatin attenuates LPS-induced inflammation in mouse macrophage RAW264.7 cells by inhibiting the JNK/NF-kappa B signaling pathway and activating the PI3K/Akt/Nrf2 pathway. Acta pharmacologica Sinica. 2018;39:1294-1304.
  12. Qian Li, Zhuoming Li, Shuya Sun, Luping Wang, Panxia Wang, Zhen Guo, Hanwei Yang, Jiantao Ye, Jing Lu*, Peiqing Liu*, PARP1 interacts with HMGB1 and promotes its nucleus export in pathological myocardial hypertrophy, Acta Pharmacologica Sinica, 2018, 0: 1-10.
  13. Yang HW, Hong HL, Luo WW, Dai CM, Chen XY, Wang LP, Li Q, Li ZQ, Liu PQ* and Li ZM*. mTORC2 facilitates endothelial cell senescence by suppressing Nrf2 expression via the Akt/GSK-3beta/C/EBPalpha signaling pathway. Acta pharmacologica Sinica. 2018;39:1837-1846.
  14. He P, Li ZM, Yue ZB, Gao H, Feng GS, Wang PX, Huang Y, Luo WW, Hong HQ, Liang LY, Chen SR* and Liu PQ*. SIRT3 prevents angiotensin -induced renal tubular epithelial-mesenchymal transition by ameliorating oxidative stress and mitochondrial dysfunction. Molecular and Cellular Endocrinology. 2018;460:1-13.
  15. Gao S, Liu XP, Wei LH, Lu J and Liu PQ*. Upregulation of alpha-enolase protects cardiomyocytes from phenylephrine-induced hypertrophy. Canadian journal of physiology and pharmacology. 2018;96:352-358.
  16. Wang PX, Li ZM, Cai SD, Li JY, He P, Huang Y, Feng GS, Luo HB, Chen SR* and Liu PQ*. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling. Acta pharmacologica Sinica. 2017;38:1257-1268.
  17. Feng GS, Zhu CG, Li ZM, Wang PX, Huang Y, Liu M, He P, Lou LL, Chen SR* and Liu PQ*. Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin-induced mouse cardiac remodeling. Acta pharmacologica Sinica. 2017;38:638-650.
  18. Chen YF#, Chen SR#, Yue ZB#, Zhang YQ, Zhou CH, Cao WW, Chen X, Zhang LK and Liu PQ*. Receptor-interacting protein 140 overexpression impairs cardiac mitochondrial function and accelerates the transition to heart failure in chronically infarcted rats. Translational Research. 2017;180:91-102.
  19. Zhang XY, Li W, Shen PY, Feng XJ, Yue ZB, Lu J, You J, Li JY, Gao H, Fang S, Li ZM* and Liu PQ*. STAT3 Suppression Is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy. Journal of Cardiovascular Pharmacology. 2016;68:204-214.
  20. Zhang BY, Jiang JM, Yue ZB, Liu SL, Ma YZ, Yu N, Gao Y, Sun SY, Chen SR* and Liu PQ*. Store-Operated Ca2+ Entry (SOCE) contributes to angiotensin -induced cardiac fibrosis in cardiac fibroblasts. Journal of Pharmacological Sciences. 2016;132:171-180.
  21. Yue ZB#, Ma YZ#, You J, Li ZM, Ding YQ, He P, Lu X, Jiang JM, Chen SR* and Liu PQ*. NMNAT3 is involved in the protective effect of SIRT3 in Ang -induced cardiac hypertrophy. Experimental Cell Research. 2016;347:261-273.
  22. Shen PY, Feng XJ, Zhang XY, Huang XY, Liu SL, Lu X, Li JY, You J, Lu J, Li ZM, Ye JT* and Liu PQ*. SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p300. Journal of Pharmacological Sciences. 2016;132:31-40.
  23. Lu J, Zhang RW, Hong HQ, Yang ZL, Sun DP, Sun SY, Guo XL, Ye JT, Li ZM* and Liu PQ*. The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy. Biochimica Et Biophysica Acta-Molecular Cell Research. 2016;1863:3027-3039.
  24. Lu J, Sun DP, Liu ZP, Li M, Hong HQ, Liu C, Gao S, Li H, Cai Y, Chen SR, Li ZM, Ye JT* and Liu PQ*. SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy. Translational Research. 2016;172:96-112.
  25. Liu ZP, Wang JJ, Huang XY, Li ZM* and Liu PQ*. Deletion of sirtuin 6 accelerates endothelial dysfunction and atherosclerosis in apolipoprotein E-deficient mice. Translational Research. 2016;172:18-29.
  26. Li JY#, Gao H#, Huang JY, Wang PX, Huang Y, Luo WW, Zhang XY, Shen PY, You J, Cai SD, Li ZM* and Liu PQ*. PKC zeta interacts with STAT3 and promotes its activation in cardiomyocyte hypertrophy. Journal of Pharmacological Sciences. 2016;132:15-23.
  27. Gao Y#, Liu YJ#, Hong L, Yang ZL, Cai XR, Chen XY, Fu YY, Lin YJ, Wen WJ, Li ST, Liu XG, Huang HQ, Vogt A, Liu PQ*, Yin XM* and Li M*. Golgi-associated LC3 lipidation requires V-ATPase in noncanonical autophagy. Cell death & disease. 2016;7.
  28. Wei JX#, Lv LH#, Wan YL#, Cao Y#, Li GL, Lin HM, Zhou R, Shang CZ, Cao J, He H, Han QF, Liu PQ*, Zhou G* and Min J*. Vps4A Functions as a Tumor Suppressor by Regulating the Secretion and Uptake of Exosomal MicroRNAs in Human Hepatoma Cells. Hepatology. 2015;61:1284-1294.
  29. Tan KM#, Liu ZP#, Wang JJ, Xu SW, You TH* and Liu PQ*. Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor kappa B signaling. Translational Research. 2015;165:374-386.
  30. Liu ZP#, Xu SW#, Huang XY, Wang JJ, Gao S, Li H, Zhou CH, Ye JT, Chen SR, Jin ZG and Liu PQ*. Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1). British Journal of Pharmacology. 2015;172:5661-5675.
  31. Liu XP#, Gao H#, Huang XY, Chen YF, Feng XJ, He YH, Li ZM* and Liu PQ*. Peroxisome proliferator-activated receptor gamma coactivator 1 alpha protects cardiomyocytes from hypertrophy by suppressing calcineurin-nuclear factor of activated T cells c4 signaling pathway. Translational Research. 2015;166:459-473.
  32. Li Q, Shen PY, Zeng SY and Liu PQ*. TIEG1 Inhibits Angiotensin-induced Cardiomyocyte Hypertrophy by Inhibiting Transcription Factor GATA4. Journal of Cardiovascular Pharmacology. 2015;66:196-203.
  33. He YH, Zhang LK, Li ZM, Gao H, Yue ZB, Liu ZP, Liu XP, Feng XJ and Liu PQ*. RIP140 triggers foam-cell formation by repressing ABCA1/G1 expression and cholesterol efflux via liver X receptor. Febs Letters. 2015;589:455-460.
  34. Gao S#, Li H#, Feng XJ, Li M, Liu ZP, Cai Y, Lu J, Huang XY, Wang JJ, Li Q, Chen SR, Ye JT* and Liu PQ*. alpha-Enolase plays a catalytically independent role in doxorubicin-induced cardiomyocyte apoptosis and mitochondrial dysfunction. Journal of Molecular and Cellular Cardiology. 2015;79:92-103.
  35. Gao H#, Feng XJ#, Li ZM#, Li M, Gao S, He YH, Wang JJ, Zeng SY, Liu XP, Huang XY, Chen SR* and Liu PQ*. Downregulation of adipose triglyceride lipase promotes cardiomyocyte hypertrophy by triggering the accumulation of ceramides. Archives of Biochemistry and Biophysics. 2015;565:76-88.
  36. Feng XJ#, Gao H#, Gao S, Li ZM, Li H, Lu J, Wang JJ, Huang XY, Liu M, Zou J, Ye JT* and Liu PQ*. The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1. British Journal of Pharmacology. 2015;172:2852-2863.
  37. Cao WW, Chen JW, Chen YF, Chen SR, Chen X, Huang HQ and Liu PQ*. Advanced glycation end products induced immune maturation of dendritic cells controls heart failure through NF-kappa B signaling pathway. Archives of Biochemistry and Biophysics. 2015;580:112-120.
  38. Zou J, Li H, Chen X, Zeng SY, Ye JT, Zhou CH, Liu M, Zhang LK, Yu N, Gan XH, Zhou HF, Xian ZW, Chen SR* and Liu PQ*. C/EBP beta knockdown protects cardiomyocytes from hypertrophy via inhibition of p65-NF kappa B. Molecular and Cellular Endocrinology. 2014;390:18-25.
  39. Zhang LK#, Chen YF#, Yue ZB, He YH, Zou J, Chen SR, Liu M, Chen X, Liu ZP, Liu XP, Feng XJ, Li M and Liu PQ*. The p65 subunit of NF-kappa B involves in RIP140-mediated inflammatory and metabolic dysregulation in cardiomyocytes. Archives of Biochemistry and Biophysics. 2014;554:22-27.
  40. Yu Y#, Chen SR#, Xiao CY, Jia YY, Guo JL, Jiang JM* and Liu PQ*. TRPM7 is involved in angiotensin induced cardiac fibrosis development by mediating calcium and magnesium influx. Cell Calcium. 2014;55:252-260.
  41. Yu N, Jiang JM, Yu Y, Li H, Huang XY, Ma YZ, Zhang LK, Zou J, Zhang BY, Chen SR* and Liu PQ*. SLC41A1 knockdown inhibits angiotensin -induced cardiac fibrosis by preventing Mg2+ efflux and Ca2+ signaling in cardiac fibroblasts. Archives of Biochemistry and Biophysics. 2014;564:74-82.
  42. Xu SW*#, Liu ZP# and Liu PQ*. Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis. International Journal of Cardiology. 2014;172:313-317.
  43. Xu SW*, Liu ZP, Huang Y, Chen JW, Chen SR, Shen XY, Huang HQ and Liu PQ*. Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone A from Danshen in a mouse model of atherosclerosis. International Journal of Cardiology. 2014;174:878-880.
  44. Xu SW*, Bai P, Little PJ and Liu PQ*. Poly(ADP-ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications. Medicinal Research Reviews. 2014;34:644-675.
  45. Wang JJ#, Liu ZP#, Feng XJ, Gao S, Xu SW and Liu PQ*. Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling. Archives of Biochemistry and Biophysics. 2014;562:22-30.
  46. Ma YZ, Li H, Yue ZB, Guo JL, Xu SW, Xu J, Jia YY, Yu N, Zhang BY, Liu SL, Liu M, Shao WW, Chen SR* and Liu PQ*. Cryptotanshinone Attenuates Cardiac Fibrosis via Downregulation of COX-2, NOX-2, and NOX-4. Journal of Cardiovascular Pharmacology. 2014;64:28-37.
  47. Lu J, Sun DP, Gao S, Gao Y, Ye JT* and Liu PQ*. Cyclovirobuxine D Induces Autophagy-Associated Cell Death via the Akt/mTOR Pathway in MCF-7 Human Breast Cancer Cells. Journal of Pharmacological Sciences. 2014;125:74-82.
  48. Liu ZP, Wang JJ, Huang EW, Gao S, Li H, Lu J, Tian KM, Little PJ, Shen XY, Xu SW* and Liu PQ*. Tanshinone A suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. Journal of Lipid Research. 2014;55:201-213.
  49. Liu M, Ye JT, Gao S, Fang W, Li H, Geng BA, Zou J, Chen X, Chen SR, Zhang LK, Yue ZB, Ma YZ, Gao H, Li ZM* and Liu PQ*. Salvianolic acid B protects cardiomyocytes from angiotensin -induced hypertrophy via inhibition of PARP-1. Biochemical and Biophysical Research Communications. 2014;444:346-353.
  50. Liu M#, Li Z#, Chen GW, Li ZM, Wang LP, Ye JT*, Luo HB* and Liu PQ*. AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from Ang-induced hypertrophy. Molecular and Cellular Endocrinology. 2014;392:14-22.
  51. Li H#, Gao S#, Ye JT, Feng XJ, Cai Y, Liu ZP, Lu J, Li Q, Huang XY, Chen SR* and Liu PQ*. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: Role of NFATc3. Molecular and Cellular Endocrinology. 2014;382:998-1006.
  52. Gao S, Li H, Cai Y, Ye JT, Liu ZP, Lu J, Huang XY, Feng XJ, Gao H, Chen SR, Li M* and Liu PQ*. Mitochondrial binding of alpha-enolase stabilizes mitochondrial membrane: Its role in doxorubicin-induced cardiomyocyte apoptosis. Archives of Biochemistry and Biophysics. 2014;542:46-55.
  53. Chen X, Zeng SY, Zou J, Chen YF, Yue ZB, Gao Y, Zhang LK, Cao WW and Liu PQ*. Rapamycin Attenuated Cardiac Hypertrophy Induced by Isoproterenol and Maintained Energy Homeostasis via Inhibiting NF-kappa B Activation. Mediators of Inflammation. 2014.
  54. Cao WW, Chen JW, Chen YF, Chen X and Liu PQ*. Advanced Glycation End Products Promote Heart Failure Through Inducing the Immune Maturation of Dendritic Cells. Applied Biochemistry and Biotechnology. 2014;172:4062-4077.
  55. Zou J, Le K, Xu SW, Chen JW, Liu ZP, Chao XJ, Geng B, Luo JN, Zeng SY, Ye JT* and Liu PQ*. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-alpha partly via preventing p65-NF kappa B binding to NFATc4. Molecular and Cellular Endocrinology. 2013;370:103-112.
  56. Zeng SY#, Chen X#, Chen SR, Li Q, Wang YH, Zou J, Cao WW, Luo JN, Gao H and Liu PQ*. Upregulation of Nox4 Promotes Angiotensin - Induced Epidermal Growth Factor Receptor Activation and Subsequent Cardiac Hypertrophy by Increasing ADAM17 Expression. Canadian Journal of Cardiology. 2013;29:1310-1319.
  57. Yu SS#, Cai Y#, Ye JT, Pi RB, Chen SR, Liu PQ*, Shen XY* and Ji Y*. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappa B-dependent transcriptional activity. British Journal of Pharmacology. 2013;168:117-128.
  58. Xu SW*, Ogura S, Chen JW, Little PJ, Moss J and Liu PQ*. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cellular and Molecular Life Sciences. 2013;70:2859-2872.
  59. Xu SW*, Liu ZP and Liu PQ*. HDL cholesterol in cardiovascular diseases: The good, the bad, and the ugly? International Journal of Cardiology. 2013;168:3157-3159.
  60. Xu SW and Liu PQ*. Tanshinone -A: new perspectives for old remedies. Expert Opinion on Therapeutic Patents. 2013;23:149-153.
  61. Xu J, Jia YY, Chen SR, Ye JT, Bu XZ, Hu Y, Ma YZ, Guo JL and Liu PQ*. (E)-1-(4-ethoxyphenyl)-3-(4-nitrophenyl)-prop-2-en-1-one suppresses LPS-induced inflammatory response through inhibition of NF-kappa B signaling pathway. International Immunopharmacology. 2013;15:743-751.
  62. Wang P#, Zhou SG#, Xu LP#, Lu Y, Yuan X, Zhang HJ, Li RF, Fang J and Liu PQ*. Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: Blockade by tanshinone A. Journal of Ethnopharmacology. 2013;145:152-161.
  63. Geng B#, Cai Y#, Gao S, Lu J, Zhang L, Zou J, Liu M, Yu SS, Ye JT* and Liu PQ*. PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1. Biochemical and Biophysical Research Communications. 2013;430:944-950.
  64. Cai Y#, Yu SS#, Chen TT, Gao S, Geng BA, Yu Y, Ye JT* and Liu PQ*. EGCG inhibits CTGF expression via blocking NF-kappa B activation in cardiac fibroblast. Phytomedicine. 2013;20:106-113.
     
    5年申请或已授权的专利:
    1、李民,刘培庆等。一种自噬关键蛋白ATG4B酶抑制剂及其应用; 申请号201710071824.1,公开号CN106905217A。 
    2、刘培庆等。用于防治肺纤维化的隐丹参酮类及其应用。国家发明专利公开号:201710013231.X
    3、刘培庆等。中国发明专利授权。一种多肽及其在制备抗心衰和炎性反应药物中的应用;申请号,200810218732.2,公开号CN101401930,授权号:ZL 200810218732.2;授权日:2010.12.29
    4、刘培庆等。中国发明专利公开实审。一种用于预防和治疗动脉粥样硬化的药物组合物,申请号201110073572.9,公开号CN102125567A,专利号: ZL 201110073572.9,授权时间:2012.11
    5、黄河清,刘培庆等。中国发明专利授权。一种治疗糖尿病的药物组合物及其制备方法,申请号200510101169.7,公开号CN1813957,授权号:ZL 200510101169.7,授权日2007.09.12,成功转让并已进入3期临床试验。

 5年主编及参编专著:

1、主编《药理学实验实训教程》. 科学出版社,20156月出版,ISBN 978-7- 03-044688-6.

2、参编“国家卫生和计划生育委员会“十三五”规划教材、全国高等医药教材建设研究会“十三五”规划教材”《药理学(第8版)》. 人民卫生出版社,主编:朱依谆、殷明,20168月出版。主笔“抗动脉粥样硬化药物”一章,共1.5万字。

3、参编《心脑血管药理学》.主笔《治疗心力衰竭的药物》一章,约3万字.目前二校中,预计2019年出版。

4、参编《高等药理学》.主笔第六篇第二章《心力衰竭治疗药物》,2万字. 目前校稿中,预计2019年出版。

获奖情况

12010年广东省科学技术一等奖。基于天然产物结构改造的靶向性药物先导化合物的基础性研究。证书编号:B17-0-1-01-D01;获奖人:古练权;黄志纾;欧田苗;卜宪章;刘培庆;马林;黄世亮;安林坤;谭嘉恒; 卢宇靖;毕惠嫦。

22010年度高等学校科学研究优秀成果奖自然科学奖二等奖(教育部)。基于天然产物结构改造的靶向性药物先导化合物的基础性研究。证书编号:2010-100;获奖人:古练权;黄志纾;欧田苗;黄民;刘培庆;卜宪章;谭嘉恒;黄世亮;安林坤;马林;卢宇靖。